AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10917988 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC(calf)
Number of subjects: 45
Study 10917988 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC(foot+calf)
Number of subjects: 45
Study 8863764 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1893291 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human calcitonin 0.25 mg
Number of subjects: 60
Study 1893291 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human calcitonin 0.125 mg
Number of subjects: 60
Study 1893291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6380896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen mustard (0.1 mg/kg body weight) administered in 3 intravenous bolus injections over 3-5 weeks
Number of subjects: 33
Study 6380896 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 cases)
Number of subjects: 33
Study 28750588 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training of shoulder/neck muscles for ten weeks using elastic resistance bands.
Number of subjects: 60
Study 28750588 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic and posture correction (control group).
Number of subjects: 60
Study 27077354 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging group
Number of subjects: 1393
Study 24128168 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct refluxing technique
Number of subjects: 102
Study 24128168 — intervention group
Group type: COMPARATOR
Intervention: SLET technique
Number of subjects: 102
Study 21993365 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS) and pill count
Number of subjects: 470
Study 21993365 — intervention group
Group type: COMPARATOR
Intervention: Pill count alone (control group)
Number of subjects: 470
Study 21993365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 470
Study 21993365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 470
Study 20859153 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion below the fascia using ropivacaine and ketoprofene
Number of subjects: 56
Study 20859153 — intervention group
Group type: COMPARATOR
Intervention: Continuous wound infusion above the fascia using ropivacaine and ketoprofene
Number of subjects: 56
Study 18408049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised furosemide 40 mg
Number of subjects: 15
Study 18408049 — intervention group
Group type: COMPARATOR
Intervention: Nebulised 0.9% saline
Number of subjects: 15
Study 18408049 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 16160802 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict metabolic control with insulin administration (fasting glucose levels to 90 mg/dl and 130 mg/dl postprandially)
Number of subjects: 875
Study 16160802 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 875
Study 14559315 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban diet
Number of subjects: 33
Study 14559315 — intervention group
Group type: COMPARATOR
Intervention: Rural diet
Number of subjects: 33
Study 14559315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 33
Study 11219953 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey Laminolact (therapeutic/prophylactic dragee)
Number of subjects: 44
Study 9002334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 40000
Study 9002334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega-dose capsule distribution (100,000 IU for 6-12 months; 200,000 IU for 1-5 years)
Number of subjects: 40000
Study 9002334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40000
Study 1618248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of quinine (500 mg)
Number of subjects: 10
Study 1618248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of quinine (500 mg)
Number of subjects: 10
Study 1618248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and intravenous administration of quinine (500 mg)
Number of subjects: 10
Study 6204486 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol-17-propionate
Number of subjects: 17
Study 6204486 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 17
Study 31227432 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone (1000 mg daily) + Dasatinib (100 mg daily)
Number of subjects: 26
Study 31227432 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone (1000 mg daily)
Number of subjects: 26
Study 30897992 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ measurements of polyp size
Number of subjects: 40
Study 30897992 — intervention group
Group type: EXPERIMENTAL
Intervention: First in situ measurement
Number of subjects: 40
Study 30897992 — intervention group
Group type: EXPERIMENTAL
Intervention: Second in situ measurement
Number of subjects: 40
Study 30897992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-fixation measurement
Number of subjects: 40
Study 30897992 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of ≥20 mm polyps
Number of subjects: 40
Study 28282396 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria vaccine (FMP2.1/AS02A)
Number of subjects: 400
Study 28282396 — intervention group
Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 400
Study 26122751 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions focused around expectations and planning for the future
Number of subjects: 200
Study 23348980 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily)
Number of subjects: 250
Study 23348980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 21542741 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene-receptor antagonist (LTRA)
Number of subjects: 318
Study 21542741 — intervention group
Group type: COMPARATOR
Intervention: Inhaled glucocorticoid
Number of subjects: 318
Study 21542741 — intervention group
Group type: COMPARATOR
Intervention: Long-acting beta(2)-agonist (LABA)
Number of subjects: 318
Study 19542792 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 or 120 mg/d
Number of subjects: 1332
Study 19542792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1332
Study 16494150 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive dilational tracheostomy
Number of subjects: 100
Study 16494150 — intervention group
Group type: COMPARATOR
Intervention: Forceps dilational tracheostomy
Number of subjects: 100
Study 12527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly maintenance interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 12527545 — intervention group
Group type: COMPARATOR
Intervention: Monthly clinical management and pill placebo
Number of subjects: 0
Study 12527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance IPT
Number of subjects: 0
Study 12527545 — intervention group
Group type: COMPARATOR
Intervention: Supportive clinical management and pill placebo
Number of subjects: 0
Study 11132902 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 157
Study 11132902 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 157
Study 9296894 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CT examination at admission (< 72 hrs)
Number of subjects: 47
Study 9296894 — intervention group
Group type: COMPARATOR
Intervention: Control CT scans (2‐4 weeks later)
Number of subjects: 47
Study 8291420 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular injections of hyaluronan (placebo control: saline injections)
Number of subjects: 1
Study 8291420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole treatment
Number of subjects: 1
Study 8291420 — intervention group
Group type: EXPERIMENTAL
Intervention: Local and systemic amphotericin B, systemic 5‐fluorocytosine and surgical synovectomy
Number of subjects: 1
Study 8291420 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitation of joint cartilage proteoglycan fragments in synovial fluid
Number of subjects: 1
Study 3549806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 153
Study 3549806 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil solution
Number of subjects: 153
Study 3549806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to 3% minoxidil after 4 months)
Number of subjects: 153
Study 29457986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro-motor stimulation for 5 min twice a day
Number of subjects: 102
Study 29457986 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 102
Study 27553432 — intervention group
Group type: COMPARATOR
Intervention: Olaparib 300 mg bid for 5 days (multiple dosing)
Number of subjects: 228
Study 27553432 — intervention group
Group type: COMPARATOR
Intervention: Olaparib 100 mg (single dose)
Number of subjects: 228
Study 27553432 — intervention group
Group type: COMPARATOR
Intervention: Olaparib 300 mg (single dose)
Number of subjects: 228
Study 24941841 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) combined with general intravenous anesthesia
Number of subjects: 60
Study 24941841 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (control group)
Number of subjects: 60
Study 22515432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention supporting the psychological need for autonomy
Number of subjects: 0
Study 22515432 — intervention group
Group type: COMPARATOR
Intervention: Rationale-only condition (not supporting autonomy)
Number of subjects: 0
Study 22515432 — intervention group
Group type: COMPARATOR
Intervention: Forced-choice condition (not supporting autonomy)
Number of subjects: 0
Study 20843301 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive intervention based on a modified version of the international model of assertive community treatment
Number of subjects: 60
Study 20843301 — intervention group
Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 60
Study 18208642 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin zeta
Number of subjects: 313
Study 18208642 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 313
Study 16155276 — intervention group
Group type: EXPERIMENTAL
Intervention: +ISO (58 g protein powder/d containing 83 mg isoflavones/d)
Number of subjects: 150
Study 16155276 — intervention group
Group type: COMPARATOR
Intervention: -ISO (ethanol-extracted soy-protein powder containing 3 mg isoflavones)
Number of subjects: 150
Study 12514575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined carotid endarterectomy (CEA) and coronary artery bypass grafting (CABG)
Number of subjects: 10561
Study 10383525 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 424
Study 10383525 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 10 mg
Number of subjects: 424
Study 10383525 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 424
Study 8877824 — intervention group
Group type: EXPERIMENTAL
Intervention: Student service
Number of subjects: 0
Study 8877824 — intervention group
Group type: COMPARATOR
Intervention: Formal health care service
Number of subjects: 0
Study 8877824 — intervention group
Group type: COMPARATOR
Intervention: No service
Number of subjects: 0
Study 1889971 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol combined with polyoestradiol phosphate (EE/EP)
Number of subjects: 24
Study 1889971 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate (EM)
Number of subjects: 24
Study 1889971 — intervention group
Group type: COMPARATOR
Intervention: bilateral orchiectomy
Number of subjects: 24
Study 6794158 — intervention group
Group type: EXPERIMENTAL
Intervention: Samson circuit
Number of subjects: 0
Study 6794158 — intervention group
Group type: COMPARATOR
Intervention: Magill (Mapleson A) circuit
Number of subjects: 0
Study 30618025 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling (MN)
Number of subjects: 20
Study 30618025 — intervention group
Group type: COMPARATOR
Intervention: Neodymium:yttrium–aluminum–perovskite 1340 nm non‐ablative fractional laser (NAFL)
Number of subjects: 20
Study 30618025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MN and NAFL
Number of subjects: 20
Study 30618025 — intervention group
Group type: COMPARATOR
Intervention: NAFL
Number of subjects: 20
Study 30618025 — intervention group
Group type: EXPERIMENTAL
Intervention: MN
Number of subjects: 20
Study 28912936 — intervention group
Group type: EXPERIMENTAL
Intervention: QSNYL-FEYL combination
Number of subjects: 41
Study 28912936 — intervention group
Group type: COMPARATOR
Intervention: QSNYL
Number of subjects: 41
Study 27488365 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning ingestion of warfarin
Number of subjects: 0
Study 27488365 — intervention group
Group type: COMPARATOR
Intervention: Evening ingestion of warfarin (control)
Number of subjects: 0
Study 25151492 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX) - 10min bouts of thrice‐weekly jumping plus capoeira
Number of subjects: 151
Study 25151492 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX)
Number of subjects: 151
Study 25151492 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - usual PE activities
Number of subjects: 151
Study 25151492 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 151
Study 18845520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Neurotoxicity Questionnaire (PNQ)
Number of subjects: 61
Study 15110062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal initiation of services (PP+HS)
Number of subjects: 439
Study 15110062 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal Healthy Steps (HS)
Number of subjects: 439
Study 15110062 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 439
Study 11371277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 173
Study 11371277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pulsatile cardiopulmonary bypass)
Number of subjects: 173
Study 9142578 — intervention group
Group type: COMPARATOR
Intervention: heated humidifier (control condition)
Number of subjects: 10
Study 9142578 — intervention group
Group type: EXPERIMENTAL
Intervention: heat and moisture exchanger without filtering function (HME)
Number of subjects: 10
Study 9142578 — intervention group
Group type: EXPERIMENTAL
Intervention: combined heat and moisture exchanger and mechanical filter (HMEF)
Number of subjects: 10
Study 8314201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 8.00‐10.00 h (M group)
Number of subjects: 34
Study 8314201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 14.00‐16.00 h (AN group)
Number of subjects: 34
Study 8314201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 19.00‐21.00 h (NT group)
Number of subjects: 34
Study 3302121 — intervention group
Group type: EXPERIMENTAL
Intervention: Budipine (60 mg daily)
Number of subjects: 31
Study 3302121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 11883307 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (for vaginal hysterectomy)
Number of subjects: 0
Study 11883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy m. Martin
Number of subjects: 0
Study 11883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0
Study 31255482 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 95
Study 31255482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 29994806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization (HCR)
Number of subjects: 0
Study 27299457 — intervention group
Group type: EXPERIMENTAL
Intervention: SC peginterferon β‐1a 125 mcg every-2-weeks
Number of subjects: 1512
Study 27299457 — intervention group
Group type: EXPERIMENTAL
Intervention: SC peginterferon β‐1a 125 mcg every-4-weeks
Number of subjects: 1512
Study 27299457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1512
Study 27299457 — intervention group
Group type: EXPERIMENTAL
Intervention: SC peginterferon β‐1a
Number of subjects: 1512
Study 25261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with longer surgical duration (odds ratio per 10-minute increase, 1.05; 95% confidence interval, 1.03-1.07)
Number of subjects: 1828
Study 25261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with endoscopic vein harvesting (odds ratio, 1.41; 95% confidence interval, 1.16-1.71)
Number of subjects: 1828
Study 25261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with poor target artery quality (odds ratio, 1.43; 95% confidence interval, 1.11-1.84)
Number of subjects: 1828
Study 25261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative use of clopidogrel or ticlopidine (odds ratio, 1.35; 95% confidence interval, 1.07-1.69)
Number of subjects: 1828
Study 25261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient-level VGF
Number of subjects: 1828
Study 25261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall graft-level VGF
Number of subjects: 1828
Study 22323410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D (highest tertile, median concentration 30.1 ng/mL)
Number of subjects: 2039
Study 22323410 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 1,022)
Number of subjects: 2039
Study 22323410 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle group (n = 1,017)
Number of subjects: 2039
Study 20175410 — intervention group
Group type: EXPERIMENTAL
Intervention: sham-CPAP
Number of subjects: 104
Study 20175410 — intervention group
Group type: COMPARATOR
Intervention: polysomnographic measures without sham-CPAP
Number of subjects: 104
Study 17367217 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1g + Metronidazole 500 mg + Bismuth subcitrate 240 mg twice daily for two weeks (Group A)
Number of subjects: 314
Study 17367217 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1g + Furazolidone 200 mg twice daily + Bismuth subcitrate 240 mg twice daily for two weeks (Group B)
Number of subjects: 314
Study 17367217 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone regimen for the first week followed by Omeprazole + Amoxicillin + Metronidazole + Bismuth subcitrate for the second week (Group C)
Number of subjects: 314
Study 17367217 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between groups A and C)
Number of subjects: 314
Study 16202151 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 1 (current situation within the German-Diabetes-DMP)
Number of subjects: 4000
Study 16202151 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 2 (ideally implemented DMP with additional interventions)
Number of subjects: 4000
Study 16202151 — intervention group
Group type: COMPARATOR
Intervention: Routine care (without DMP)
Number of subjects: 4000
Study 12188390 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,400 mg BID of saquinavir soft gel with zidovudine and lamivudine
Number of subjects: 40
Study 12188390 — intervention group
Group type: COMPARATOR
Intervention: 1,200 mg TID of saquinavir soft gel with zidovudine and lamivudine
Number of subjects: 40
Study 10525024 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 18
Study 10525024 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 18
Study 10525024 — intervention group
Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 18
Study 7586356 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg BID
Number of subjects: 100
Study 7586356 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg TID
Number of subjects: 100
Study 7586356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2177889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 puffs à 2 mg)
Number of subjects: 12
Study 2177889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7447172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic treatment
Number of subjects: 0
Study 7447172 — intervention group
Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 0
Study 7447172 — intervention group
Group type: COMPARATOR
Intervention: Common duct exploration
Number of subjects: 0
Study 7447172 — intervention group
Group type: COMPARATOR
Intervention: Radiographic status of the gallbladder
Number of subjects: 0
Study 31997146 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk information
Number of subjects: 419
Study 31997146 — intervention group
Group type: COMPARATOR
Intervention: Generic risk information (control)
Number of subjects: 419
Study 31997146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both personalized and generic risk information
Number of subjects: 419
Study 31522845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0·2 mg
Number of subjects: 225
Study 31522845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0·1 mg
Number of subjects: 225
Study 31522845 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 225
Study 31522845 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0·2 mg vs Laser therapy
Number of subjects: 225
Study 31522845 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0·1 mg vs Laser therapy
Number of subjects: 225